Women's Health & Gynecology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer (PANKU-GYN01)

This phase 3 trial is testing a new drug called BL-B01D1 against standard chemotherapy in patients whose ovarian cancer no longer responds to platinum-based treatments. For patients with this type of resistant cancer, treatment options are limited, so BL-B01D1 could offer a new hope. The study is currently recruiting adults in China living with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

This study explores a new method using DNA markers to detect endometrial, ovarian, and cervical cancers earlier and more accurately. Early detection is important because it can lead to better treatment outcomes and potentially save lives. The trial is recruiting over 3000 participants at 24 sites across the United States, making it a large effort to improve cancer screening with a simple blood or tissue test.

Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)

This research is evaluating a low-cost HPV screening test that can be done in one visit, allowing women to receive results and treatment on the same day. This approach could reduce the number of women who do not return for follow-up care, especially in low-resource settings. The trial is recruiting 1,000 women in El Salvador and could influence cervical cancer screening programs worldwide.

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

This study is testing whether women who do not regularly get screened for cervical cancer can successfully collect their own samples at home using HPV self-collection kits. If the kits prove practical and reliable, they could improve access to screening and help catch cancer earlier in women who face barriers to clinic visits. The trial is recruiting 100 participants in the United States.

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

This phase 2 trial is studying vaginal DHEA as a treatment to improve vaginal health in women who have received radiation for gynecologic, anal, or rectal cancers. Radiation can cause symptoms like vaginal dryness and pain, which affect quality of life. This treatment could provide new relief for these symptoms and help women recover comfort after cancer therapy. The study is recruiting adults in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.